Andreas Halvorsen's BBIO Position Overview
Andreas Halvorsen (via Viking Global Investors Lp) currently holds 16.0M shares of BridgeBio Pharma, Inc. (BBIO) worth $829.89 M, representing 2.16% of the portfolio. First purchased in 2019-Q2, this long-term strategic position has been held for 26 quarters.
Based on 13F filings, Andreas Halvorsen has maintained a strategic position in BBIO, demonstrating sustained confidence in this investment. Largest reduction occurred in Q2 2025, reducing 3.5M shares.
Analysis based on 13F filings available since 2013 Q2
Andreas Halvorsen's BridgeBio Pharma (BBIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly BridgeBio Pharma (BBIO) Trades by Andreas Halvorsen
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2019 | +26.62 M | New Buy | 26.62 M | $26.97 |
| Q3 2023 | -1.5 M | Reduce 5.63% | 25.12 M | $26.37 |
| Q1 2025 | -3.07 M | Reduce 12.20% | 22.06 M | $34.57 |
| Q2 2025 | -3.5 M | Reduce 15.87% | 18.56 M | $43.18 |
| Q3 2025 | -2.58 M | Reduce 13.89% | 15.98 M | $51.94 |
Andreas Halvorsen's BridgeBio Pharma Investment FAQs
Andreas Halvorsen first purchased BridgeBio Pharma, Inc. (BBIO) in Q2 2019, acquiring 26,620,991 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Andreas Halvorsen has held BridgeBio Pharma, Inc. (BBIO) for 26 quarters since Q2 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Andreas Halvorsen's largest addition to BridgeBio Pharma, Inc. (BBIO) was in Q2 2019, adding 26,620,991 shares worth $717.97 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Andreas Halvorsen's firm, Viking Global Investors Lp, owns 15,977,849 shares of BridgeBio Pharma, Inc. (BBIO), valued at approximately $829.89 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, BridgeBio Pharma, Inc. (BBIO) represents approximately 2.16% of Andreas Halvorsen's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Andreas Halvorsen's peak holding in BridgeBio Pharma, Inc. (BBIO) was 26,620,991 shares, as reported at the end of Q2 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.